Vanguard Group
ANEB

Vanguard Group’s Anebulo Pharmaceuticals ANEB Stock Holding History

Vanguard Group’s Portfolio ANEB Stock Details ANEB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$440K Buy
435,821
+129,281
+42% +$295K ﹤0.01% 3967
2025
Q3 		$766K Buy
306,540
+90,589
+42% +$213K ﹤0.01% 3855
2025
Q2 		$311K Buy
215,951
+11,406
+6% +$13K ﹤0.01% 4014
2025
Q1 		$266K Buy
204,545
+50,509
+33% +$74.3K ﹤0.01% 4012
2024
Q4 		$259K Hold
154,036
– – ﹤0.01% 4061
2024
Q3 		$297K Buy
154,036
+163
+0.1% +$348 ﹤0.01% 4079
2024
Q2 		$420K Buy
153,873
+401
+0.3% +$1.02K ﹤0.01% 4048
2024
Q1 		$440K Buy
153,472
+469
+0.3% +$1.21K ﹤0.01% 4049
2023
Q4 		$370K Buy
153,003
+130,659
+585% +$307K ﹤0.01% 4115
2023
Q3 		$68.3K Buy
22,344
+6,312
+39% +$17.5K ﹤0.01% 4379
2023
Q2 		$37.7K Buy
+16,032
New +$40K ﹤0.01% 4487

Other funds holding ANEB

2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Vanguard Group's ANEB Position: Q4 2025 in Review

Vanguard Group increased its Anebulo Pharmaceuticals (ANEB) stake by 42% in Q4 2025, buying an estimated $295K and bringing the position to 435,821 shares worth $440K. The position accounts for ﹤0.01% of the portfolio, ranked #3967.

Vanguard Group first reported a position in ANEB in Q2 2023 and has held it in 11 quarters since. The position peaked at $766K in Q3 2025. 19 funds tracked by Wall St. Rank hold ANEB as of Q4 2025.

  • Vanguard Group held 435,821 shares of Anebulo Pharmaceuticals worth $440K as of Q4 2025.
  • Vanguard Group bought 129,281 Anebulo Pharmaceuticals shares in Q4 2025, an estimated $295K.
  • Anebulo Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3967 holding.
  • Vanguard Group first reported a position in Anebulo Pharmaceuticals in Q2 2023 and has held it in 11 quarters since.
  • Vanguard Group's Anebulo Pharmaceuticals position peaked at $766K in Q3 2025.
  • 19 funds tracked by Wall St. Rank held Anebulo Pharmaceuticals as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.